Can specific heterologous immunity boost hepatitis B vaccine responses?

Journal of Infectious Diseases

Volumn 198, Issue 3, 2008, Pages 297-298

  Diepolder, Helmut M ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; CD4+ T LYMPHOCYTE; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEMODIALYSIS PATIENT; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

HEPATITIS B; HEPATITIS B VACCINES; HUMANS;

EID: 48749083738     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/589721     Document Type: Note

References (12)

1. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006; 103:c89 -93.
2. Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand J Infect Dis 1999; 31:93-5.
3. Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low- and nonresponders after a standard three dose hepatitis B vaccine schedule - results of a postmarketing surveillance. Vaccine 1997; 15:349-52.
4. Zuckerman JN, Zuckerman AJ, Symington I, et al. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 2001; 34:798-802.
5. Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002; 20:3644-9.
6. Rendi-Wagner P, Shouval D, Genton B, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006; 24:2781-9.
7. European Medinices Agency. Product information for Fendrix, 2006. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/fendrix/H-550-PI-en. pdf. Last accessed 13 May 2008.
8. Cooper CL, Davis HL, Morris ML, et al. CPG 7909, an immunostimulatoryTLR9agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004; 24:693-701.
9. Dynavax Technologies. Dynavax and Merck & Co., Inc. report clinical hold of investigational HEPLISAV [press release]. Available at: http://investors.dynavax.com/releasedetail.cfm?ReleaseID=300049. Last accessed 13 May 2008.
10. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327-32.
11. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl 1):S3-25.
12. Cardell K, Åkerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. J Infect Dis 2008; 198:299-304 (in this issue).